Targeted radiotherapy for malignant gliomas

Current Drug Discovery Technologies

Volumn 9, Issue 4, 2012, Pages 268-279

  Oh, Daniel S ^a   Adamson, David C ^a   Kirkpatrick, John P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Charged particle therapy; Glioma; Radioimmunotherapy; Radiosurgery; Radiotherapy

Indexed keywords

EID: 84868011850     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016312803305870     Document Type: Article

References (98)

1. Brandes AA, Tosoni A, Franceschi E, et al. Glioblastoma in adults. Crit Rev Oncol Hematol 2008; 67(2): 139-52.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5): 459-66.
3. Shapiro WR, Young DF, Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol 1976; 33(7): 494-50.
4. Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49(3): 333-43. (Pubitemid 9013313)
5. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303(23): 1323-9. (Pubitemid 11194457)
6. Laperriere N, Zuraw L, Cairncross G, Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 64(3): 259-73. (Pubitemid 35254019)
7. Walker MD, Strike TA, Sheline GE, An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5(10): 1725-31. (Pubitemid 10187518)
8. Bleehen NM, Stenning SP, A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64(4): 769-74.
9. Salazar OM, Rubin P, Feldstein ML, et al. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 1979; 5(10): 1733-40. (Pubitemid 10187519)
10. Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988; 6: 279-84. (Pubitemid 18048001)
11. Yin FF, Das S, Kirkpatrick J, et al. Physics and imaging for targeting of oligometastases. Semin Radiat Oncol 2006; 16(2): 85-101.
12. Tsien C, Moughan J, Michalski JM, et al. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys 2009; 73(3): 699-708.
13. Monjazeb AM, Ayala D, Jensen C, et al. A Phase I Dose Escalation Study of Hypofractionated IMRT Field-in-Field Boost for Newly Diagnosed Glioblastoma Multiforme. Int J Radiat Oncol Biol Phys 2012; 82(2): 743-8.
14. Hochberg FH, Pruitt A, Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30(9): 907-11. (Pubitemid 10059239)
15. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989; 71(1): 1-9. (Pubitemid 19196544)
16. Kita M, Okawa T, Tanaka M, et al. [Radiotherapy of malignant glioma - prospective randomized clinical study of whole brain vs local irradiation]. Gan No Rinsho 1989; 35(11): 1289-94.
17. Thornton AF, Jr., Sandler HM, Ten Haken RK, et al. The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. Int J Radiat Oncol Biol Phys 1992; 24(4): 767-75.
18. Niyazi M, Geisler J, Siefert A, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol 2011; 99(1): 44-8.
19. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185(3): 675-86.
20. Graves EE, Nelson SJ, Vigneron DB, et al. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery 2000; 46(2): 319-26; discussion 326-8.
21. Deutsch M, Green SB, Strike TA, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1989; 16(6): 1389-96. (Pubitemid 19154320)
22. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 1996; 77(8): 1535-43.
23. Lustig RA, Seiferheld W, Berkey B, et al. Imaging response in malignant glioma, RTOG 90-06. American Journal of Clinical Oncology-Cancer Clinical Trials 2007; 30(1): 32-37. (Pubitemid 46213822)
24. Shin KH, Urtasun RC, Fulton D, et al. Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report. Cancer 1985; 56(4): 758-60. (Pubitemid 15228265)
25. Shin KH, Muller PJ, Geggie PH, Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer 1983; 52(11): 2040-3. (Pubitemid 14232244)
26. Payne DG, Simpson WJ, Keen C, et al. Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 1982; 50(11): 2301-6. (Pubitemid 13244164)
27. Horiot JC, van den Bogaert W, Ang KK, et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. Front Radiat Ther Oncol 1988; 22: 149-61.
28. Brada M, Sharpe G, Rajan B, et al. Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Radiat Oncol Biol Phys 1999; 43(2): 287-92. (Pubitemid 29091466)
29. Lee AW, Kwong DL, Leung SF, et al. Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 2002; 53(1): 75-85. (Pubitemid 34465809)
30. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): S20-7.
31. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22(9): 1583-8. (Pubitemid 41079795)
32. Phillips C, Guiney M, Smith J, et al. A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol 2003; 68(1): 23-6. (Pubitemid 37289332)
33. Bauman GS, Gaspar LE, Fisher BJ, et al. A prospective study of shortcourse radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994; 29(4): 835-9. (Pubitemid 24241325)
34. Glinski B. Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial. J Neurooncol 1993; 16(2): 167-72. (Pubitemid 23304725)
35. Malmstrom A. Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). J Clin Oncol 2010; 28(18s).
36. Kondziolka D, Flickinger JC, Bissonette DJ, et al. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 1997; 41(4): 776-83; discussion 783-5.
37. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60(3): 853-60. (Pubitemid 39311766)
38. Cardinale R, Won M, Choucair A, et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 2006; 65(5): 1422-8. (Pubitemid 44425201)
39. Shrieve DC, Alexander E, 3rd, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995; 36(2): 275-82; discussion 282-4.
40. Combs SE, Widmer V, Thilmann C, et al. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 2005; 104(10): 2168-73. (Pubitemid 41579963)
41. Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients with Recurrent Malignant Gliomas. Int J Radiat Oncol Biol Phys 2011.
42. Niyazi M, Ganswindt U, Schwarz SB, et al. Irradiation and Bevacizumab in High-Grade Glioma Retreatment Settings. Int J Radiat Oncol Biol Phys 2010.
43. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 75(1): 156-63.
44. Gutin PH, Prados MD, Phillips TL, et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 1991; 21(3): 601-6.
45. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998; 41(5): 1005-11. (Pubitemid 28377480)
46. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51(2): 343-55; discussion 355-7.
47. Sneed PK, McDermott MW, Gutin PH. Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 1997; 13(3): 157-66. (Pubitemid 27188347)
48. Tselis N, Kolotas C, Birn G, et al. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol 2007; 183(10): 563-70. (Pubitemid 47482157)
49. Patel S, Breneman JC, Warnick RE, et al. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 2000; 46(5): 1123-8; discussion 1128-30.
50. Gabayan AJ, Green SB, Sanan A, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multiinstitutional analysis. Neurosurgery 2006; 58(4): 701-9; discussion 701-9.
51. Tatter SB, Shaw EG, Rosenblum ML, et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg 2003; 99(2): 297-303. (Pubitemid 36900125)
52. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled anti-tenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20(5): 1389-97. (Pubitemid 34177447)
53. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled anti-tenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006; 24(1): 115-22. (Pubitemid 46630502)
54. Reardon DA, Zalutsky MR, Akabani G, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008; 10(2): 182-9.
55. Boiardi A, Bartolomei M, Silvani A, et al. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 2005; 72(2): 125-31. (Pubitemid 40796462)
56. Li L, Quang TS, Gracely EJ, et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg 2010; 113(2): 192-8.
57. Casaco A, Lopez G, Garcia I, et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 2008; 7(3): 333-9. (Pubitemid 351847044)
58. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005; 56(6): 1243-52; discussion 1252-3. (Pubitemid 40770440)
59. Mamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006; 24(22): 3644-50. (Pubitemid 46630539)
60. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 2006; 12(12): 3843-50.
61. Cordier D, Forrer F, Kneifel S, et al. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P - results from a phase I study. J Neurooncol 2010; 100(1): 129-36.
62. Virgolini I, Britton K, Buscombe J, et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32(2): 148-55. (Pubitemid 34311081)
63. Barth RF, Joensuu H. Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: as effective, more effective or less effective than photon irradiation? Radiother Oncol 2007; 82(2): 119-22.
64. Yamamoto T, Nakai K. Matsumura A, Boron neutron capture therapy for glioblastoma. Cancer Lett 2008; 262(2): 143-52.
65. Chanana AD, Capala J, Chadha M, et al. Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery 1999; 44(6): 1182-92; discussion 1192-3.
66. Kawabata S, Miyatake S, Nonoguchi N, et al. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl Radiat Isot 2009; 67(7-8 Suppl): S15-8.
67. Hopewell JW, Gorlia T, Pellettieri L, et al. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential. Appl Radiat Isot 2011.
68. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96. (Pubitemid 40349501)
69. Miyatake S, Kawabata S, Yokoyama K, et al. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 2009; 91(2): 199-206.
70. Carson KA, Grossman SA, Fisher JD, et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007; 25(18): 2601-6. (Pubitemid 47041234)
71. Aziz T, Peress NS, Diaz A, et al. Postmortem neuropathological features secondary to boron neutron capture therapy for glioblastoma multiforme. J Neuropathol Exp Neurol 2000; 59(1): 62-73. (Pubitemid 30069226)
72. Asbury AK, Ojemann RG, Nielsen SL, et al. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 1972; 31(2): 278-303.
73. Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 2003; 62(1-2): 101-9. (Pubitemid 36553120)
74. Laramore GE, Spence AM. Boron neutron capture therapy (BNCT) for high-grade gliomas of the brain: a cautionary note. Int J Radiat Oncol Biol Phys 1996; 36(1): 241-6. (Pubitemid 26314172)
75. Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol 2010; 7(1): 37-43.
76. Blomquist E, Bjelkengren G, Glimelius B. The potential of proton beam radiation therapy in intracranial and ocular tumours. Acta Oncol 2005; 44(8): 862-70. (Pubitemid 41780111)
77. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999; 91(2): 251-60.
78. Mizumoto M, Tsuboi K, Igaki H, et al. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2010; 77(1): 98-105.
79. Mizoe JE, Tsujii H, Hasegawa A, et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69(2): 390-6. (Pubitemid 47380082)
80. Combs SE, Kieser M, Rieken S, et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer 2010; 10: 478.
81. Combs SE, Burkholder I, Edler L, et al. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC Cancer 2010; 10: 533.
82. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. A report from the MRC Working Party on misonidazole in gliomas. Br J Radiol 1983; 56(669): 673-82.
83. Kleinberg L, Grossman SA, Carson K, et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol 2002; 20(14): 3149-55. (Pubitemid 34791105)
84. Del Rowe J, Scott C, Werner-Wasik M, et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 2000; 18(6): 1254-9. (Pubitemid 30159843)
85. Groves MD, Maor MH, Meyers C, et al. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1999; 45(1): 127-35. (Pubitemid 29380084)
86. Robins HI, Won M, Seiferheld WF, et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol 2006; 8(1): 47-52. (Pubitemid 43154450)
87. Langer CJ, Ruffer J, Rhodes H, et al. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51(1): 113-9. (Pubitemid 32758870)
88. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997-1003. (Pubitemid 40349502)
89. Ford JM, Seiferheld W, Alger JR, et al. Results of the phase I doseescalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2007; 69(3): 831-8. (Pubitemid 47418404)
90. Baumann F, Bjeljac M, Kollias SS, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004; 67(1-2): 191-200. (Pubitemid 38418268)
91. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 2006; 65(4): 1192-9.
92. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23(23): 5294-304. (Pubitemid 46206983)
93. Hall WA, Djalilian HR, Sperduto PW, et al. Stereotactic radiosurgery for recurrent malignant gliomas. Journal of Clinical Oncology 1995; 13(7): 1642-8.
94. Kong DS, Lee JI, Park K, et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 2008; 112(9): 2046-51. (Pubitemid 351574081)
95. Biswas T, Okunieff P, Schell MC, et al. Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol 2009; 4: 11.
96. Cho KH, Hall WA, Gerbi BJ, et al. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. International Journal of Radiation Oncology, Biology, Physics 1999; 45(5): 1133-41.
97. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010; 28(18): 3048-53.
98. Torcuator RG, Thind R, Patel M, et al. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 2010; 97(3): 401-7.